Should You Start Treatment or Continue Monitoring?

Few things are more stressful for parents than hearing that their child is growing more slowly than expected. Whether your child has fallen behind classmates in height, dropped percentiles on the growth chart, or simply isn't experiencing the growth spurts you expected, it's natural to wonder what comes next.

One of the most common questions families ask is whether they should begin treatment immediately or continue monitoring their child's growth over time. In some cases, parents may hear about sermorelin as a potential option, while other physicians recommend observation before considering any hormone-based therapy.

Which approach is right?

The answer depends almost entirely on why your child is experiencing delayed growth.

For many children, careful monitoring is the safest and most appropriate approach because they are simply developing later than their peers. Others may have an underlying medical condition that benefits from earlier diagnosis and, in some situations, medical treatment.

Rather than asking whether sermorelin or observation is "better," the more important question is:

What is causing my child's growth delay?

A thorough evaluation provides the information needed to answer that question and develop a personalized plan based on your child's unique growth pattern.

What Is Growth Delay?

Growth delay is not a diagnosis itself. Instead, it describes a pattern in which a child is growing more slowly than expected for their age, sex, or genetic potential.

Some children are:

• Significantly shorter than classmates.
• Growing fewer inches each year than expected.
• Entering puberty later than average.
• Falling downward on standardized growth charts.

These findings can have many different causes, which is why physicians avoid making treatment decisions based on height alone.

A complete Pediatric Growth Evaluation Checklist helps physicians understand whether a child's growth pattern represents a normal variation or an underlying medical condition that deserves further investigation.

Why Finding the Cause Comes Before Choosing Treatment

Parents understandably want to know what treatment will help their child grow taller.

However, experienced pediatric growth specialists begin with a different question:

Why isn't this child growing normally?

Several very different conditions can produce similar symptoms.

These include:

Constitutional Growth Delay

Many children diagnosed with Constitutional Growth Delay are simply late bloomers.

These children often:

• Grow steadily throughout childhood.
• Have a delayed bone age.
• Enter puberty later than friends.
• Continue growing after many classmates have stopped.

Although they may appear much shorter during middle school or early high school, many eventually reach an adult height close to their family's genetic expectations.

Because of this, observation is frequently the most appropriate initial recommendation.

Growth Hormone Deficiency

Children with Growth Hormone Deficiency produce inadequate amounts of growth hormone to support normal childhood growth.

Possible findings include:

• Slow annual height gain.
• Declining growth percentiles.
• Delayed skeletal maturation.
• Reduced growth velocity.
• Low growth hormone production during stimulation testing.

Unlike constitutional growth delay, this condition may benefit from medical treatment after appropriate diagnostic evaluation.

Familial Short Stature

Some children simply inherit shorter height from their parents.

These children usually:

• Grow at a normal rate.
• Have normal hormone testing.
• Reach an adult height that reflects family genetics.

Medical treatment is often unnecessary because the child's growth pattern is healthy despite being below average.

Idiopathic Short Stature

Some children remain significantly shorter than expected despite otherwise normal testing.

This condition is known as Idiopathic Short Stature.

Management depends on multiple factors including predicted adult height, growth velocity, remaining growth potential, and whether the child meets established treatment criteria.

Other Medical Conditions

Growth delay may also result from:

• Nutritional deficiencies.
• Chronic gastrointestinal disease.
• Kidney disease.
• Thyroid disorders.
• Genetic syndromes.
• Certain Pituitary Disorders affecting hormone production.

Because the list of possible causes is broad, accurate diagnosis always comes before deciding whether observation or treatment is appropriate.

What Does Observation Actually Mean?

Parents sometimes worry that "observation" means nothing is being done.

In reality, observation—often called watchful monitoring—is an active medical strategy.

The goal is to determine whether a child's growth pattern continues normally over time while avoiding unnecessary medication.

Observation commonly includes:

• Scheduled height measurements every 3–6 months.
• Calculation of annual growth velocity.
• Review of puberty progression.
• Repeat Bone Age Test for Child Height when appropriate.
• Laboratory evaluation if new concerns develop.
• Updated predicted adult height calculations.

This structured approach allows physicians to recognize changes early while giving naturally delayed children time to demonstrate their own growth pattern.

When Observation Is Often the Best First Step

Observation is commonly recommended when several reassuring findings are present.

These include:

• Normal Poor Growth Velocity for skeletal age.
• Consistent growth along the same percentile.
• Delayed bone age without concerning progression.
• Family history of late puberty.
• Normal laboratory findings.
• No evidence of chronic illness.
• Predicted adult height consistent with family genetics.

Many children meeting these criteria ultimately experience a spontaneous growth spurt during adolescence.

For these families, careful monitoring often avoids unnecessary medical treatment while preserving the opportunity to intervene later if growth patterns change.

What Is Sermorelin?

Sermorelin is a synthetic version of growth hormone-releasing hormone (GHRH), a naturally occurring hormone produced by the hypothalamus.

Rather than supplying growth hormone directly, sermorelin works by stimulating the pituitary gland to produce and release the body's own growth hormone.

As growth hormone production increases, the liver may produce more insulin-like growth factor-1 (IGF-1), an important hormone involved in bone growth and normal childhood development.

Parents interested in learning more about this therapy often begin by reviewing Sermorelin for Children, which explains how the medication works, how it differs from recombinant growth hormone, and situations in which physicians may discuss it.

It is important to understand that recombinant human growth hormone is approved by the U.S. Food and Drug Administration for specific pediatric conditions. Sermorelin does not have the same FDA approval status for increasing height in children, and decisions regarding its use should always involve careful discussion with a qualified pediatric specialist.

Observation and Sermorelin Are Not Opposing Strategies

One common misconception is that families must choose either observation or sermorelin immediately.

In reality, observation is frequently the first stage of the diagnostic process.

Monitoring allows physicians to collect valuable information regarding:

• Growth velocity.
• Puberty timing.
• Bone age progression.
• Hormone levels.
• Predicted adult height.

Only after understanding these factors can families and clinicians have an informed discussion about whether continued observation or another treatment approach is appropriate.

Beginning with an accurate diagnosis often prevents both unnecessary treatment and unnecessary delays in children who truly need additional medical evaluation.

Sermorelin vs. Observation: How Do They Compare?

Although families often think of observation and sermorelin as competing options, they actually serve very different purposes.

Observation focuses on understanding a child's natural growth pattern before introducing medical therapy.

Sermorelin attempts to stimulate the body's natural production of growth hormone by acting on the pituitary gland.

The most appropriate choice depends on whether a child's slow growth represents a normal developmental variation or an underlying medical condition.

Observation	Sermorelin
Monitors natural growth over time	Stimulates the body's natural growth hormone release
No medication required	Requires regular injections
Appropriate for many late bloomers	May be considered in selected situations after careful evaluation
Minimal medical risk	Requires physician supervision and ongoing monitoring
Allows diagnosis to become clearer over time	Should only be considered after a comprehensive growth evaluation

The goal should never be to start treatment as quickly as possible. Instead, the goal is to make the right decision based on accurate medical information.

What Does the Current Medical Evidence Show?

Observation has been part of pediatric endocrinology for decades and remains the standard approach for many children with delayed but otherwise healthy growth patterns.

Children diagnosed with Constitutional Growth Delay frequently experience:

• Delayed puberty
• Delayed bone age
• Later adolescent growth spurts
• Adult heights close to their genetic potential

Because of this, observation remains an evidence-supported strategy for appropriately selected children.

Sermorelin, on the other hand, has considerably less long-term pediatric evidence regarding final adult height than recombinant human growth hormone.

While sermorelin increases endogenous growth hormone release, families should understand that published pediatric outcome data remain more limited.

For this reason, a careful discussion with a pediatric growth specialist is essential before considering hormone-based therapy.

Why Growth Hormone Testing May Be Necessary

Before discussing treatment, physicians often recommend determining whether a child actually has inadequate growth hormone production.

Testing may include:

• Growth Hormone Deficiency Testing Protocol in Children
• Growth Hormone Lab Values in Children
• IGF-1 measurement
• IGFBP-3 measurement
• Bone age evaluation
• Growth chart review

These studies help determine whether a child's growth delay represents:

• Constitutional delay
• Familial short stature
• Hormone deficiency
• Another endocrine disorder

Without this information, selecting treatment becomes much more difficult.

Why IGF-1 Is Often Measured

Parents frequently ask why physicians measure IGF-1 instead of growth hormone itself.

Growth hormone is released in short bursts throughout the day and night.

Because of these natural fluctuations, a single blood sample rarely reflects overall hormone production.

Instead, physicians often evaluate IGF-1 Levels Low in a Child, because IGF-1 provides a better picture of the body's long-term response to growth hormone.

A low result does not automatically diagnose growth hormone deficiency.

Rather, it helps determine whether additional endocrine testing is appropriate.

Timing Matters More Than Many Parents Realize

Whether observation or treatment is ultimately chosen, timing remains one of the most important factors in pediatric growth.

Children grow because their growth plates remain open during childhood.

As puberty progresses:

• Growth plates mature.
• Bone age advances.
• Remaining growth potential decreases.

Families often assume they can simply "wait until next year."

Sometimes that is entirely appropriate.

Other times, an additional year represents a meaningful portion of the child's remaining growth window.

Understanding Growth Hormone Therapy Timeline in Children helps families appreciate why physicians recommend early evaluation when concerning growth patterns develop.

The Importance of Puberty

Puberty dramatically changes growth potential.

Children entering puberty often experience their fastest annual growth.

However, this rapid growth period is temporary.

As puberty progresses, growth plates gradually close until additional height gain is no longer possible.

This is one reason physicians carefully evaluate Delayed Puberty and Height Growth when assessing children with slow growth.

Understanding where a child is within puberty often influences both observation recommendations and treatment discussions.

Could Nutrition or Lifestyle Be Responsible?

Not every child with slow growth has an endocrine disorder.

Physicians also evaluate:

• Caloric intake
• Protein intake
• Vitamin D status
• Zinc
• Iron
• Sleep quality
• Exercise habits
• Chronic illness

Parents frequently find Supplements That Help Kids Grow Taller and How to Help Children Grow Taller Naturally helpful for understanding realistic lifestyle strategies that support healthy growth.

These approaches should never replace appropriate medical evaluation, but they often complement an overall growth plan.

When Should Families Seek Another Opinion?

Parents sometimes feel uncertain after being told to "wait another year."

If your child continues:

• Falling further behind classmates
• Losing height percentiles
• Growing fewer inches each year
• Showing delayed puberty
• Having abnormal laboratory findings

a second evaluation may be appropriate.

Many families benefit from seeking a Second Opinion Growth Hormone Therapy Kids consultation before making long-term treatment decisions.

Additional review of growth charts, bone age, and laboratory testing may clarify whether continued observation remains appropriate.

Questions Parents Should Ask

Before deciding between observation and any hormone-based therapy, consider discussing these questions with your child's specialist:

• What diagnosis best explains my child's growth?
• Is observation still appropriate?
• How much growth potential remains?
• Does my child have Low IGF-1 or another hormone abnormality?
• Is additional testing recommended?
• What benefits are realistically expected?
• What happens if we continue monitoring for another six months?

These conversations help families make informed decisions rather than reacting solely to height concerns.

Frequently Asked Questions

Is observation considered treatment?

Observation is an active medical management strategy that includes regular growth measurements, bone age assessment, and ongoing physician follow-up.

Does sermorelin work the same as growth hormone?

No. Sermorelin stimulates the body's own growth hormone release, while recombinant human growth hormone directly replaces growth hormone.

Can every child with delayed growth receive sermorelin?

No. Treatment decisions depend on the child's diagnosis, remaining growth potential, medical history, and physician assessment.

Is waiting ever the right decision?

Absolutely. Many children with constitutional growth delay eventually experience normal catch-up growth without medication.

Should families always seek evaluation before considering hormone therapy?

Yes. A comprehensive growth evaluation provides the information needed to determine whether observation or treatment is the safest and most appropriate path.

The Bottom Line

Choosing between sermorelin and observation should never be based on height alone.

Instead, the decision begins with understanding why a child is growing more slowly than expected.

Many children benefit from careful observation because they simply have delayed development or inherited shorter stature.

Others may have an underlying endocrine disorder that deserves additional evaluation and, in some cases, medical treatment.

The safest approach is one that is individualized, evidence-informed, and guided by careful assessment of growth velocity, bone age, laboratory findings, puberty, genetics, and overall health.

Parents who understand the reason behind their child's growth pattern are better equipped to make confident decisions that support both healthy physical development and long-term well-being.

Medically Reviewed By

Dr. Devin Stone, ND

Dr. Devin Stone is a Doctor of Naturopathic Medicine and founder of HGHforChildren.com. His clinical focus includes pediatric growth optimization, growth hormone deficiency, delayed bone age assessment, constitutional growth delay, IGF-1 evaluation, and evidence-informed therapies designed to help children maximize healthy growth potential.

References

• Pediatric Endocrine Society
• Growth Hormone Research Society
• Endocrine Society
• American Academy of Pediatrics
• National Institutes of Health (NIH)
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Hormone Research in Paediatrics
• Journal of Clinical Endocrinology & Metabolism